Urolithins impair cell proliferation, arrest the cell cycle and induce apoptosis in UMUC3 bladder cancer cells Joana LiberalAnália CarmoMaria Teresa Batista PRECLINICAL STUDIES 20 June 2017 Pages: 671 - 681
Copper (II) complexes of bidentate ligands exhibit potent anti-cancer activity regardless of platinum sensitivity status Mohamed WehbeCody LoMarcel B. Bally PRECLINICAL STUDIES Open access 21 July 2017 Pages: 682 - 690
Synthesis, characterization, and evaluation of Cd[L-proline]2, a novel histone deacetylase inhibitor that induces epigenetic modification of histone deacetylase isoforms in A549 cells Anusha ChidambaramArunachalam SekarRavikumar Vilwanathan PRECLINICAL STUDIES 03 August 2017 Pages: 691 - 705
Induction of accelerated senescence by the microtubule-stabilizing agent peloruside A Ariane ChanConnie GilfillanJohn H. Miller PRECLINICAL STUDIES 22 July 2017 Pages: 706 - 717
Anti-invasive effects of CXCR4 and FAK inhibitors in non-small cell lung carcinomas with mutually inactivated p53 and PTEN tumor suppressors Miodrag DragojJasna BankovicTijana Stankovic PRECLINICAL STUDIES 22 July 2017 Pages: 718 - 732
Novel inhibitors of lysine (K)-specific Demethylase 4A with anticancer activity Hyo Jeong LeeBo-Kyoung KimSun-Young Han PRECLINICAL STUDIES 14 September 2017 Pages: 733 - 741
A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel Lillian M. SmythKelsey R. MonsonDavid M. Hyman PHASE I STUDIES 09 March 2017 Pages: 742 - 750
Human mass balance study and metabolite profiling of 14C-niraparib, a novel poly(ADP-Ribose) polymerase (PARP)-1 and PARP-2 inhibitor, in patients with advanced cancer Lotte van AndelZ. ZhangJ. H. Beijnen PHASE I STUDIES Open access 16 March 2017 Pages: 751 - 765
Phase I trial of the oral smoothened inhibitor sonidegib in combination with paclitaxel in patients with advanced solid tumors A. StathisD. Hessfor the Swiss Group for Clinical Cancer Research (SAKK) PHASE I STUDIES 20 March 2017 Pages: 766 - 772
A phase 1, open label, dose escalation study to investigate the safety, tolerability, and pharmacokinetics of MG1102 (apolipoprotein(a) Kringle V) in patients with solid tumors Gun Min KimTony ReidHyun Cheol Chung PHASE I STUDIES 28 March 2017 Pages: 773 - 781
Phase I trial and pharmacokinetic study of tanibirumab, a fully human monoclonal antibody to vascular endothelial growth factor receptor 2, in patients with refractory solid tumors Su Jin LeeSeon Young LeeYoung Suk Park PHASE I STUDIES Open access 08 April 2017 Pages: 782 - 790
Safety and effectiveness of eribulin in Japanese patients with locally advanced or metastatic breast cancer: a post-marketing observational study Junichiro WatanabeYoshinori ItoToshiaki Saeki PHASE II STUDIES Open access 29 June 2017 Pages: 791 - 799
Phase II basket trial of perifosine monotherapy for recurrent gynecologic cancer with or without PIK3CA mutations Kosei HasegawaMasahiro KagabuTadashi Kimura PHASE II STUDIES 02 September 2017 Pages: 800 - 812
Metformin as a repurposed therapy in advanced non-small cell lung cancer (NSCLC): results of a phase II trial Anish B. ParikhPeter KozuchBenjamin P. Levy PHASE II STUDIES 22 September 2017 Pages: 813 - 819
Mechanisms of cancer cell killing by sea cucumber-derived compounds Teresa Liliana WargasetiaWidodo REVIEW Open access 18 September 2017 Pages: 820 - 826
Comparison of reporting phase I trial results in ClinicalTrials.gov and matched publications D. ShepshelovichH. GoldvaserP. L. Bedard REVIEW 14 September 2017 Pages: 827 - 833
Treatment-related serious adverse events and fatal adverse events with regorafenib in cancer patients: a meta-analysis of phase 3 randomized controlled trials Meihui CaoFeifei LiJingdong Zhang REVIEW 22 September 2017 Pages: 834 - 838
Successful osimertinib rechallenge in a patient with advanced non-small cell lung cancer following osimertinib-induced interstitial lung disease after treatment with nivolumab Nobuaki MamesayaHirotsugu KenmotsuToshiaki Takahashi SHORT REPORT Open access 02 May 2017 Pages: 839 - 841
Clinical parameters associated with anti-programmed death-1 (PD-1) inhibitors-induced tumor response in melanoma patients Valentine HeidelbergerFrançois GoldwasserSélim Aractingi SHORT REPORT 31 May 2017 Pages: 842 - 847
Osimertinib reactivated immune-related colitis after treatment with anti-PD1 antibody for non-small cell lung cancer Tomoyoshi TakenakaKoji YamazakiSadanori Takeo SHORT REPORT 10 June 2017 Pages: 848 - 850